59 studies found for:    "Kidney Neoplasms" AND (woman OR women OR female)
Show Display Options
Rank Status Study
21 Completed Zinc Supplements in Lowering Cadmium Levels in Smokers
Conditions: Bladder Cancer;   Cervical Cancer;   Esophageal Cancer;   Gastric Cancer;   Head and Neck Cancer;   Kidney Cancer;   Leukemia;   Liver Cancer;   Lung Cancer;   Pancreatic Cancer;   Tobacco Use Disorder
Intervention: Dietary Supplement: zinc oxide
22 Completed
Has Results
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Conditions: Bladder Cancer;   Cervical Cancer;   Esophageal Cancer;   Gastric Cancer;   Head and Neck Cancer;   Kidney Cancer;   Leukemia;   Liver Cancer;   Lung Cancer;   Pancreatic Cancer;   Tobacco Use Disorder
Interventions: Drug: nicotine lozenge;   Drug: nicotine patch
23 Completed Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
Conditions: Endometrial Cancer;   Kidney Cancer;   Metastatic Cancer;   Ovarian Cancer;   Pheochromocytoma;   Sarcoma
Interventions: Biological: filgrastim;   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Procedure: conventional surgery
24 Completed Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
Conditions: Endometrial Cancer;   Kidney Cancer;   Ovarian Cancer;   Pheochromocytoma;   Sarcoma
Interventions: Biological: filgrastim;   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Drug: isolated perfusion;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Radiation: radiation therapy
25 Recruiting Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma;   Hereditary Leiomyomatosis and Renal Cell Cancer;   Papillary Renal Cell Carcinoma, Sporadic
Interventions: Drug: Vandetanib;   Drug: Metformin
26 Recruiting A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Conditions: Malignant Rhabdoid Tumors (MRT);   Rhabdoid Tumors of the Kidney (RTK);   Atypical Teratoid Rhabdoid Tumors (ATRT);   Selected Tumors With Rhabdoid Features;   Synovial Sarcoma;   INI1-negative Tumors;   Malignant Rhabdoid Tumor of Ovary;   Renal Medullary Carcinoma;   Epithelioid Sarcoma
Intervention: Drug: Tazemetostat
27 Active, not recruiting Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Conditions: Solid Tumor;   Adult Central Nervous System Germ Cell Tumor;   Adult Rhabdomyosarcoma;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Soft Tissue Sarcoma;   Ewing Sarcoma;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Ovarian Mixed Germ Cell Tumor;   Previously Untreated Childhood Rhabdomyosarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Extragonadal Germ Cell Tumor;   Recurrent Extragonadal Non-seminomatous Germ Cell Tumor;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Neuroblastoma;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: busulfan;   Drug: melphalan;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation;   Other: pharmacological study;   Procedure: autologous bone marrow transplantation
28 Completed Brivanib Metastatic Renal Cell Carcinoma
Condition: Male and Female Subjects 18 Years of Age and Older With Metastatic Renal Cell Carcinoma. Eligible Patients Must Have Undergone and Failed Prior Treatment.
Interventions: Drug: Brivanib alaninate;   Genetic: Polymerase chain reaction;   Other: Iodine I 124 chimeric monoclonal antibody G250;   Procedure: Positron emission tomography/computed tomography;   Genetic: Protein expression analysis;   Other: Immunohistochemistry
29 Recruiting A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Conditions: HLRCC;   Metastatic Papillary RCC
Interventions: Drug: Bevacizumab;   Drug: Erlotinib
30 Recruiting Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, and Urologic Cancers
Conditions: Healthy, no Evidence of Disease;   Localized Transitional Cell Cancer of the Renal Pelvis and Ureter;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Psychosocial Effects of Cancer and Its Treatment;   Recurrent Bladder Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Uterine Sarcoma;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage II Bladder Cancer;   Stage II Renal Cell Cancer;   Stage II Urethral Cancer;   Stage IIA Cervical Cancer;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Cervical Cancer;   Stage IIB Colon Cancer;   Stage IIB Gastric Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIB Uterine Sarcoma;   Stage IIC Colon Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Bladder Cancer;   Stage III Pancreatic Cancer;   Stage III Renal Cell Cancer;   Stage III Urethral Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Cervical Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Cancer;   Stage IV Gastric Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IV Urethral Cancer;   Stage IVA Cervical Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Cervical Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Stage IVB Uterine Sarcoma;   Ureter Cancer
Interventions: Other: educational intervention;   Behavioral: telephone-based intervention;   Procedure: quality-of-life assessment;   Other: questionnaire administration
31 Recruiting Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Breast Carcinoma;   Carcinoma of Unknown Primary Origin;   Endometrial Carcinoma;   Esophageal Carcinoma;   Lung Carcinoma;   Malignant Head and Neck Neoplasm;   Melanoma;   Ovarian Carcinoma;   Renal Pelvis and Ureter Urothelial Carcinoma;   Testicular Lymphoma
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Veliparib
32 Completed Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Conditions: Advanced Adult Primary Liver Cancer;   Anaplastic Thyroid Cancer;   Bone Metastases;   Carcinoma of the Appendix;   Distal Urethral Cancer;   Fallopian Tube Cancer;   Gastrinoma;   Glucagonoma;   Inflammatory Breast Cancer;   Insulinoma;   Liver Metastases;   Localized Unresectable Adult Primary Liver Cancer;   Lung Metastases;   Male Breast Cancer;   Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Parathyroid Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Newly Diagnosed Carcinoma of Unknown Primary;   Occult Non-small Cell Lung Cancer;   Pancreatic Polypeptide Tumor;   Primary Peritoneal Cavity Cancer;   Proximal Urethral Cancer;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adrenocortical Carcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Carcinoma of Unknown Primary;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Esophageal Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Parathyroid Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Intestine Cancer;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Thyroid Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Vaginal Cancer;   Recurrent Vulvar Cancer;   Skin Metastases;   Small Intestine Adenocarcinoma;   Somatostatinoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adrenocortical Carcinoma;   Stage III Bladder Cancer;   Stage III Cervical Cancer;   Stage III Colon Cancer;   Stage III Endometrial Carcinoma;   Stage III Esophageal Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Gastric Cancer;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Ovarian Epithelial Cancer;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Rectal Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Anal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Anal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Adrenocortical Carcinoma;   Stage IV Anal Cancer;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Gastric Cancer;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Pancreatic Cancer;   Stage IV Papillary Thyroid Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer;   Stage IVB Vulvar Cancer;   Thyroid Gland Medullary Carcinoma;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer;   Urethral Cancer Associated With Invasive Bladder Cancer;   WDHA Syndrome
Interventions: Biological: recombinant interleukin-12;   Biological: ABI-007/carboplatin/trastuzumab
33 Recruiting Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
Conditions: Renal Cell Carcinoma;   Colorectal Adenocarcinoma;   Non-squamous Non-small Cell Lung Cancer;   Platinum-refractory Ovarian Carcinoma;   Cervical Carcinoma
Interventions: Drug: Nintedanib;   Drug: Bevacizumab
34 Recruiting Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Conditions: Advanced Solid Tumors;   Endometrial Cancer;   Melanoma;   Microsatellite Unstable (MSI) Colorectal Cancer;   MMR-deficient Tumors;   Non-small Cell Lung Cancer;   Renal Cell Carcinoma;   Head and Neck Squamous Cell Carcinoma;   Triple Negative Breast Cancer;   Transitional Cell Carcinoma of the Genitourinary Tract;   Pancreatic Ductal Adenocarcinoma
Interventions: Drug: Pembrolizumab;   Drug: INCB039110;   Drug: INCB050465
35 Recruiting Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
Conditions: Advanced Malignant Neoplasm;   Cervical Squamous Cell Carcinoma;   Endometrial Carcinoma;   Malignant Uterine Neoplasm;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Head and Neck Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Ovarian Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Solid Neoplasm;   Stage III Bladder Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Breast Cancer;   Stage IV Ovarian Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Bladder Cancer;   Stage IVA Cervical Cancer;   Stage IVB Bladder Cancer;   Stage IVB Cervical Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nanoparticle Albumin-Bound Rapamycin;   Other: Quality-of-Life Assessment
36 Recruiting Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions)
Conditions: Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
Intervention: Drug: Entrectinib
37 Recruiting A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Conditions: Non-small Cell Lung Cancer (NSCLC);   Squamous Cell Carcinoma of the Head and Neck (SCCHN);   Ovarian Carcinoma;   Colorectal Cancer (CRC);   Renal Cell Carcinoma (RCC) (Phase ll Only);   Glioblastoma (GBM) (Phase ll Only);   Melanoma (Phase 1 Only)
Intervention: Drug: Combination of varlilumab and nivolumab
38 Recruiting Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors
Conditions: Adult Solid Neoplasm;   Metastatic Melanoma;   Metastatic Renal Cell Cancer;   Recurrent Colorectal Carcinoma;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Ovarian Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Ziv-Aflibercept
39 Recruiting TAA-Specific CTLS for Solid Tumors (TACTASOM)
Conditions: Bladder Cancer;   Breast Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastric Cancer;   Head and Neck Cancer;   HCC;   Lung Cancer;   Melanoma;   Neuroblastoma;   Sarcoma (Osteo-, Synovial, Rhabdomyo-, Etc);   Pancreatic Cancer;   Prostate Cancer;   Renal Cell Carcinoma;   Thyroid Cancer
Intervention: Biological: TAA-Specific CTLs
40 Recruiting A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)
Conditions: Malignant Solid Tumour;   Lymphoma, Large B-Cell, Diffuse;   Carcinoma, Non-Small-Cell Lung;   Transitional Cell Carcinoma of Genitourinary Tract;   Triple Negative Breast Cancer;   Carcinoma, Squamous Cell of Head and Neck;   Ovarian Neoplasms;   Adenocarcinoma of the Endometrium;   Renal Cell Carcinoma
Interventions: Drug: MK-3475;   Drug: INCB024360

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-59) Show next page of results    Last Page
Indicates status has not been verified in more than two years